About IMB Dx

IMBdx offers a liquid biopsy platform that combines artificial intelligence and genomic analysis for early cancer detection and ongoing patient monitoring. Their technology enables precise screening and monitoring of various cancer types through simple blood tests, improving treatment planning and patient outcomes.

```xml <problem> Detecting cancer early and monitoring its progression often requires invasive procedures. Traditional methods can be burdensome for patients and may not provide a comprehensive view of the disease's status. </problem> <solution> IMBdx offers a liquid biopsy platform that uses artificial intelligence (AI) and genomic analysis to improve cancer screening and monitoring through simple blood tests. Their platform, called AlphaLiquid®, analyzes circulating tumor DNA (ctDNA) to provide insights into cancer detection, recurrence monitoring, and treatment response. The technology aims to offer a less invasive and more comprehensive approach to cancer management, potentially leading to earlier detection, more informed treatment decisions, and improved patient outcomes. The platform supports various applications, including cancer screening (CancerFind™), monitoring cancer recurrence after surgery (CancerDetect™), and monitoring of advanced cancer in patients (AlphaLiquid® 100/HRR). </solution> <features> - AI-driven analysis of ctDNA from liquid biopsies - Non-invasive cancer screening and monitoring - AlphaLiquid® 100/HRR for monitoring advanced cancer patients - CancerDetect™ for early monitoring of cancer recurrence after surgery - CancerFind™ for cancer screening via blood tests - Services for clinical use, biopharma, and research applications </features> <target_audience> The primary target audience includes oncologists, hospitals, research institutions, and biopharmaceutical companies involved in cancer treatment and research, as well as individuals seeking cancer screening. </target_audience> <revenue_model> IMBdx generates revenue through sales of its liquid biopsy tests (AlphaLiquid®, CancerDetect™, and CancerFind™) and related services to healthcare providers, research institutions, and biopharmaceutical companies. </revenue_model> ```

What does IMB Dx do?

Where is IMB Dx located?

IMB Dx is based in Seoul, South Korea.

When was IMB Dx founded?

IMB Dx was founded in 2018.

How much funding has IMB Dx raised?

IMB Dx has raised 18000000.

Location

Seoul, South Korea

Founded

2018

Funding

18000000

Employees

33 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

IMB Dx

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

imbdx.com 300+

Crunchbase

Founded 2018 – Seoul, South Korea

Funding

Estimated Funding

$10M+

Team (30+)

No team information available.

Company Description

Problem

Detecting cancer early and monitoring its progression often requires invasive procedures. Traditional methods can be burdensome for patients and may not provide a comprehensive view of the disease's status.

Solution

IMBdx offers a liquid biopsy platform that uses artificial intelligence (AI) and genomic analysis to improve cancer screening and monitoring through simple blood tests. Their platform, called AlphaLiquid®, analyzes circulating tumor DNA (ctDNA) to provide insights into cancer detection, recurrence monitoring, and treatment response. The technology aims to offer a less invasive and more comprehensive approach to cancer management, potentially leading to earlier detection, more informed treatment decisions, and improved patient outcomes. The platform supports various applications, including cancer screening (CancerFind™), monitoring cancer recurrence after surgery (CancerDetect™), and monitoring of advanced cancer in patients (AlphaLiquid® 100/HRR).

Features

AI-driven analysis of ctDNA from liquid biopsies

Non-invasive cancer screening and monitoring

AlphaLiquid® 100/HRR for monitoring advanced cancer patients

CancerDetect™ for early monitoring of cancer recurrence after surgery

CancerFind™ for cancer screening via blood tests

Services for clinical use, biopharma, and research applications

Target Audience

The primary target audience includes oncologists, hospitals, research institutions, and biopharmaceutical companies involved in cancer treatment and research, as well as individuals seeking cancer screening.

Revenue Model

IMBdx generates revenue through sales of its liquid biopsy tests (AlphaLiquid®, CancerDetect™, and CancerFind™) and related services to healthcare providers, research institutions, and biopharmaceutical companies.